InsiderTrades.com logo
Did You See Trump’s Bombshell Exec. Order 001?
From Banyan Hill Publishing   |   Ad
Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."
I put all the details together for you here — but please hurry. 

ARTV Insider Trading

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): $29,999,976.00
Insider Selling (Last 12 Months): $0.00

Artiva Biotherapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Artiva Biotherapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Artiva Biotherapeutics Share Price & Price History

Current Price: $11.11
Price Change: ▲ Price Increase of +1.11 (11.10%)
As of 12/20/2024 06:31 PM ET

This chart shows the closing price history over time for ARTV up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
Missed Nvidia? Buy Elon Musk’s “Silent Partner”
From Brownstone Research   |   Ad
In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my favorite stocks. Today, it’s probably the most popular stock in the world. I believe this Elon Musk “silent partner” could be the next big AI winner.
So please click here to see the details because a lot of people could get rich.

Artiva Biotherapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/22/2024Global Strategic Fund I VenbioMajor ShareholderBuy416,666$12.00$4,999,992.001,936,637View SEC Filing Icon  
7/22/2024Yong-Jun HuhDirectorBuy2,083,332$12.00$24,999,984.003,306,900View SEC Filing Icon  
See Full Table
Is Starlink Set For The Largest IPO In History?
From Paradigm Press   |   Ad
He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000!
Click here now for the urgent details.

SEC Filings (Institutional Ownership Changes) for Artiva Biotherapeutics (NASDAQ:ARTV)

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at ARTV by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Artiva Biotherapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
11/27/2024Franklin Resources Inc.520,301$7.44M0.0%N/A2.142%Search for SEC Filing on Google Icon
11/19/2024Barclays PLC19,616$0.30M0.0%N/A0.081%Search for SEC Filing on Google Icon
11/16/2024Geode Capital Management LLC308,930$4.77M0.0%N/A1.272%Search for SEC Filing on Google Icon
11/15/2024Barclays PLC19,616$0.30M0.0%N/A0.081%Search for SEC Filing on Google Icon
11/15/2024Wellington Management Group LLP194,108$2.91M0.0%N/A0.799%Search for SEC Filing on Google Icon
11/15/2024State Street Corp86,559$1.34M0.0%N/A0.356%Search for SEC Filing on Google Icon
11/15/2024Samsara BioCapital LLC291,666$4.51M0.9%N/A1.201%Search for SEC Filing on Google Icon
11/15/2024RA Capital Management L.P.9,853,302$152.23M1.8%N/A40.565%Search for SEC Filing on Google Icon
11/15/2024RTW Investments LP148,844$2.30M0.0%N/A0.613%Search for SEC Filing on Google Icon
11/14/2024Acuta Capital Partners LLC44,000$0.68M0.6%N/A0.181%Search for SEC Filing on Google Icon
11/14/2024MetLife Investment Management LLC8,733$0.14M0.0%N/A0.036%Search for SEC Filing on Google Icon
11/13/2024BNP Paribas Financial Markets2,728$42K0.0%N/A0.011%Search for SEC Filing on Google Icon
11/12/2024Charles Schwab Investment Management Inc.40,293$0.62M0.0%N/A0.166%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Artiva Biotherapeutics logo
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.
Read More on Artiva Biotherapeutics

Today's Range

Now: $11.11
Low: $9.68
High: $11.41

50 Day Range

MA: $11.64
Low: $9.97
High: $14.47

52 Week Range

Now: $11.11
Low: $9.68
High: $17.31

Volume

352,756 shs

Average Volume

121,128 shs

Market Capitalization

$269.85 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Artiva Biotherapeutics?

Artiva Biotherapeutics' top insider investors include:
  1. Yong-Jun Huh (Director)
  2. Global Strategic Fund I Venbio (Major Shareholder)
Learn More about top insider investors at Artiva Biotherapeutics.

Who are the major institutional investors of Artiva Biotherapeutics?

Artiva Biotherapeutics' top institutional investors include:
  1. RA Capital Management L.P. — 40.57%
  2. Franklin Resources Inc. — 2.14%
  3. Geode Capital Management LLC — 1.27%
  4. Samsara BioCapital LLC — 1.20%
  5. Wellington Management Group LLP — 0.80%
  6. RTW Investments LP — 0.61%
Learn More about top institutional investors of Artiva Biotherapeutics stock.

Which major investors are buying Artiva Biotherapeutics stock?

During the previous quarter, ARTV stock was acquired by institutional investors including:
  1. RA Capital Management L.P.
  2. Franklin Resources Inc.
  3. Geode Capital Management LLC
  4. Samsara BioCapital LLC
  5. Wellington Management Group LLP
  6. RTW Investments LP
  7. State Street Corp
  8. Acuta Capital Partners LLC
In the last year, these company insiders have bought Artiva Biotherapeutics stock:
  1. Yong-Jun Huh (Director)
  2. Global Strategic Fund I Venbio (Major Shareholder)
Learn More investors buying Artiva Biotherapeutics stock.
Did You See Trump’s Bombshell Exec. Order 001?
From Banyan Hill Publishing   |   Ad
Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."
I put all the details together for you here — but please hurry.